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Gene Expression Profiling of Lichen Planus Reflects
CXCL9þ -Mediated Inflammation and Distinguishes
this Disease from Atopic Dermatitis and Psoriasis
Joerg Wenzel1,5, Bettina Peters2,5, Sabine Zahn1, Michael Birth2, Kay Hofmann2, Daniel Ku¨sters2,
Stefan Tomiuk2, Jens M. Baron3, Hans F. Merk3, Cornelia Mauch4, Thomas Krieg4, Thomas Bieber1,
Thomas Tu¨ting1 and Andreas Bosio2
Here, we present data of a gene expression profiling approach to apply the diagnostic value and pathological
significance of this method in different inflammatory skin diseases, using whole skin biopsies. Initially, SAGETM
was performed to identify frequent tags differentially expressed in various skin diseases. On the basis of these
results, a new skin pathology-oriented PIQORTM microarray was designed. Lichen planus (LP) was chosen as a
model disease to evaluate this system. Controls included healthy skin, atopic dermatitis (AD), and psoriasis
(Pso). Gene expression analyses using the topic-defined microarray followed by unclassified clustering was able
to discriminate LP from AD and Pso. Genes significantly expressed in LP included type I IFN inducible genes and
a specific chemokine expression pattern. The CXCR3 ligand, CXCL9, was the most significant marker for LP. In
situ hybridization and immunohistochemistry confirmed the results and revealed that keratinocytes are type I
IFN producers in LP skin lesions. Our results show that gene expression profiling using a skin-specific
microarray is a reliable method to identify patients with LP in the chosen context and reflect recent models
concerning the pathogenesis of this disease. Gene expression profiling might complement the diagnostic
spectrum in dermatology and may provide new pathogenetic insights.
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INTRODUCTION
Currently, the diagnosis of skin disease is primarily based on
clinical and histological findings. Molecular approaches,
including PCR, various techniques of in situ hybridization
(ISH), and cDNA microarrays, have lately complemented
these established methods (Sra et al., 2005). Gene expression
profiling is a powerful method, which simultaneously reveals
the transcriptional activity of large numbers of genes on the
mRNA level (Sugiura et al., 2005). Recent studies showed
that transcription of ‘‘marker genes’’ can be characteristic for
specific skin disorders, such as atopic dermatitis (AD) and
psoriasis (Pso), and provide insights in the pathogenesis of
these conditions (Nomura et al., 2003; Quekenborn-Trinquet
et al., 2005). Here, we tested a new approach for the use of
gene expression profiling in skin disease. We hypothesized
that expression analyses of a combination of selected genes
may specifically identify individual skin disorders and could
thus potentially be of diagnostic value in addition to
established methods. Furthermore, we hoped to discover
new pathogenetic mechanisms which might provide novel
targets for therapeutic intervention.
Our approach included a three-step proceeding: First,
SAGETM analysis of pooled skin biopsies was performed to
identify all tags differentially expressed in various skin
diseases versus healthy skin. SAGE gives an overview of a
cell’s complete gene activity by capturing all mRNAs,
rewriting them into DNA, and cutting a small tag from each
one, which are then identified computer based by a
sequencing machine (Buss and Bosio, 2005). Based on these
results and literature data, a new skin pathology-oriented
PIQORTM microarray was designed, which included 1,542
genes. This microarray was used to reveal the gene expression
profile in every single patient. Following, computer-based
hierarchical clustering was performed to receive an impartial
classification of skin samples and to identify potential marker
genes. Third, results were confirmed by ISH and immunohis-
tochemistry (IHC) and correlated to the corresponding patient
data stored in the SkinSAYSTM database (see Supplement Text).
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Lichen planus (LP) was chosen as model disease to get a
greater insight in this approach, since the disorder is well
characterized by typical clinical and histological findings. It
is a T-cell-mediated inflammatory disease of the skin and
mucous membranes of unknown origin with a lifetime risk
among 0.5–1%. LP presents clinically with characteristic
itching flat-topped papules and plaques. Histological charac-
teristics include a lymphocytic interface dermatitis with
acanthosis and hypergranulosis. IFN-driven, autoreactive
CD8þ T cells, recognizing epithelial antigens, are supposed
to play an important pathologic role (Sugerman et al., 2000;
Santoro et al., 2004; Wenzel et al., 2006). For control
purposes, AD and Pso were chosen as typical examples of
common, well-characterized T cellular inflammatory skin
disorders.
This study shows that gene expression profiling followed
by unclassified clustering is a reliable method to identify
patients with LP in the chosen context, reflects known
pathogenetic factors, and may reveal new starting points for
therapeutic intervention in this condition.
RESULTS
SAGE analyses reveals IFN signature and unique expression
of CXCL9 in LP skin biopsies
SAGE analyses were performed with pooled mRNA, which
was extracted from skin samples of 20 patients with LP, AD,
Pso, and healthy controls (HC), respectively. In each pool,
approximately 12,000–13,000 tags were identified. Figure 1a
gives an overview about the number of genes which were
significantly differentially expressed in the investigated skin
disorders, when compared with HC (Po0.01). Sixty genes
were specifically upregulated in LP, which are given in
Table 1. This group was clearly dominated by type I IFN
inducible genes (MX1 and IFITM1), and genes reflecting IFN-
associated inflammation (NF-kB, CXCL9 and major histo-
compatibility complex (MHC)). Sixteen common genes were
differentially expressed in all the three disorders, including
cytokeratin 17 and the S100 proteins A2, A7 (psoriasin), and
A9 (calgranulin) (Table 2).
The identified tags were classified following the gene
ontology clusters (http://www.geneontology.org). All three
inflammatory skin disorders showed some common features:
genes important for the structural consistent of the epidermis,
actin cytoskeleton organization and biogenesis, protein-
specific binding, transmission of nerve impulse, and synaptic
transmission were upregulated, while genes reflecting gas
transport and oxygen binding were decreased (Figure 1b).
Gene clusters, which were specifically upregulated in LP
were the CXCR3 ligands, and genes reflecting immune
response (humoral and cellular), antigen binding, receptor
binding, humoral defense mechanisms, complement activity,
cytokine activity, as well as genes reflecting cytotoxic activity
(lytic vaculoles and proteasome activator). Importantly, the
CXCR3 ligand cluster included tags, specific for all three
ligands. Among those, CXCL9 showed the strongest expres-
sion (0:13.8-fold increased when compared with HC),
whereas CXCL10 and CXCL11 were only slightly increased
when compared with HC (0:1.9 and 0:0.98, respectively). An
increased translation of genes coding for molecules involved
in antigen presentation (endogenous and exogenous antigen),
MHC class I and II, and apoptosis was found in LP and AD
(Figure 1b).
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Figure 1. Comparative results of SAGE analyses of whole skin samples in different inflammatory skin disorders. SAGE analyses were performed with pooled
mRNA, which was extracted from skin samples of 20 patients with lichen planus (LP), atopic dermatitis (AD), psoriasis (Pso), and healthy controls (HC),
respectively. In each pool, approximately 12,000–13,000 tags were identified. (a) VENN diagram of genes, which were significantly differentially expressed
(at Po0.01) in the investigated skin disorders, when compared with HC. Subsequently, these tags were classified following the gene ontology clusters.
(b) Overview about gene clusters which were specifically found in LP, compared with the expression in AD and Pso.
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Table 1. Complete list of tags which were specifically found in LP
Tag Relative expressions LP HC Description
CATACACTCTC 27.1 13.78 0 CXCL9, chemokine (C–X–C motif) ligand
CTCCTGGGCGC 23.23 11.81 0 CALML3, calmodulin-like
AAGGGCTCCTG 21.3 10.82 0 KRT16, keratin 16
ACAGCGCTGAC 19.36 9.84 0 HLA-DRB1, major histocompatibility complex, class II, DR-b1
GGGGCTGGAGG 19.36 9.84 0 PLXND1, plexin D1
CTGCTAGGAAA 19.36 9.84 0 TRAM1, translocation-associated membrane protein 1
ACCATTGGATT 17.42 8.86 0 IFITM1, interferon-induced transmembrane protein 1 (9-27)
CGGGGTGGCCG 15.49 7.87 0 COMP, cartilage oligomeric matrix protein
GACCAGAAAAA 15.49 7.87 0 COX6A1, cytochrome c oxidase subunit VIa polypeptide 1
TGAGCCTCGTG 15.49 7.87 0 ENO1, enolase 1, (a)
GGAAGGGGAGG 15.49 7.87 0 NF-kB2
GGAGGGATCAG 13.55 13.78 1.02 ILK, integrin-linked kinase
TGGCTCCTCCC 13.55 13.78 1.02 LCP1, lymphocyte cytosolic protein 1 (L-plastin)
GCAGTTCTGAC 13.55 6.89 0 HLA-DRB1, major histocompatibility complex, class II, DR-b1
AGCAAACTGAA 13.55 6.89 0 LAP3, leucine aminopeptidase 3
GCGGTTGTGGC 13.55 6.89 0 LAPTM5, lysosomal-associated multispanning membrane protein 5
GAGGCCATCCC 13.55 6.89 0 LSM7, LSM7 homolog, U6 small nuclear RNA-associated
CCCGACGTGCC 13.55 6.89 0 NDUFA3, NADH dehydrogenase (ubiquinone) 1a subcomplex
AGCTTGTGGCC 13.55 6.89 0 RAMP3, receptor (calcitonin) activity modifying protein 3
CTGGGAGAGGC 13.55 6.89 0 RNPEPL1, arginyl aminopeptidase (aminopeptidase B)-like 1
GGCCCCTCACC 11.62 11.81 1.02 IGFBP6, insulin-like growth factor binding protein 6
AGTGCCGTGTG 10.65 10.82 1.02 MX1, myxovirus (influenza virus) resistance 1, p78
GGGGCAGGGCC 9.68 9.84 1.02 EIF5A, eukaryotic translation initiation factor 5A
GGGGGTGGATG 9.68 9.84 1.02 FASTK, Fas-activated serine/threonine kinase
GCAGTGGGAAA 9.68 9.84 1.02 LTB, lymphotoxin-b (TNF superfamily, member 3)
GCTCCCAGACT 9.68 9.84 1.02 SYNGR2, synaptogyrin 2
AAGAAGCAGGG 9.68 9.84 1.02 TMEM59, transmembrane protein 59
GGCTGGTCTCC 9.68 9.84 1.02 VKORC1, vitamin K epoxide reductase complex, subunit 1
GACGGCGCAGG 7.26 14.76 2.03 ECGF1, endothelial cell growth factor 1 (platelet-derived)
GTGCTGGACCT 6.78 13.78 2.03 PSME2, proteasome (prosome, macropain) activator subunit 2
GGGCCCAGGAG 6.78 13.78 2.03 GSDMDC 1, gasdermin domain containing 1
TGCAGCACGAG 6.45 19.68 3.05 HLA-B, major histocompatibility complex, class I, B
CAGGAACGGGG 6.29 12.79 2.03 MAP2K2, mitogen-activated protein kinase kinase 2
GGCTGGGGGCC 5.52 56.09 10.17 PFN1, profilin 1
GGGGGTCACCG 5.49 16.73 3.05 ATP5G1
GGTAGCCTGGG 4.64 14.76 3.05 DDB1, damage-specific DNA binding protein 1, 127 kDa
GGCTTTACCCT 4.6 18.7 4.07 EIF5A, eukaryotic translation initiation factor 5A
GGGGCAACAGC 4.52 13.78 3.05 CD52, CD52 molecule
GTGGGGCCAAG 4.52 13.78 3.05 FOLR2, Folate receptor 2 (fetal)
CGACCCCACGC 3.71 22.63 6.1 APOE, apolipoprotein E
CATGTTGGGGT 3.39 34.44 10.17 FTH1, ferritin heavy chain polypeptide 1 (minor tag)
GGGTCTGAGGG 3.33 61.01 18.3 SLURP-1, secreted Ly-6/uPAR-related protein 1
GACTGTGCCAC 3.23 19.68 6.1 DYNLL1, dynein, light chain, LC8-type 1
Table 1 continued on following page
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PIQOR analyses confirm and extend the results of SAGE
analyses on an individual basis
We examined the gene expression on an individual basis
using a topic-defined microarray (PIQOR) comprising 1,542
skin-associated genes, which were chosen based on the
earlier SAGE results and literature data. For analysis, the
profiles of 20 patients of each of the above-mentioned
inflammatory skin diseases were randomly selected out of
altogether more than 300 profiles stored in the SkinSAYSTM
database (see Supplement Text). To verify the results of the
SAGE analysis, we specifically explored the expression of 80
genes associated with the GO keywords ‘‘interferon,’’
‘‘apoptosis,’’ ‘‘MHC,’’ ‘‘chemokine,’’ ‘‘B cell,’’ and ‘‘T cell’’.
In general, PIQOR analyses for the selected genes
confirmed the earlier SAGE results, but provided also
additional information of unique gene expression patterns.
Table 1. continued
Tag Relative expressions LP HC Description
GGAGGTGGGGC 3.18 22.63 7.12 GRN, granulin
CGAATGTCCTT 3.04 21.65 7.12 KRT5, keratin 5
ATCCGCGAGGC 2.9 35.42 12.2 CLSP, calmodulin-like skin protein
GGCCGCGTTCG 2.9 23.62 8.13 RPS17, ribosomal protein S17
CCCTGGGTTCT 2.54 41.33 16.26 BAX, BCL2-associated X protein
GATCAGGCCAG 2.18 35.42 16.26 COL3A1, collagen, type III, a1
CTGACCTGTGT 2.07 61.01 29.48 HLA-B, major histocompatibility complex, class I, B
GTTCACATTAG 1.98 183.0 92.5 HLA-DR antigens-associated invariant chain (CD74 antigen)
TGGAAATGACC 1.84 74.78 40.66 COL1A1, collagen, type I, a1
GGCCACGTAGC 1.63 84.62 51.84 Adipsin, major tag
GTTGTGGTTAA 1.61 254.7 158.6 B2M, b2-microglobulin
This table displays all tags which were specifically found in LP skin lesions by SAGE analyses. Given is the absolute expression in lichen planus (LP) and
healthy control (HC) as well as the relative expression in LP (LP/HC).
Table 2. Common tags found in LP, AD, and Pso
Tag counts Ratios
Tag HC LP AD Pso LP AD Pso
Unigene
cluster Description
TTCCCTTACCC 2.03 20.66 29.84 25.95 10.16 14.84 12.95 Hs.244349 LCE3D, late cornified envelope 3D
CCAGGGGAGAA 4.07 31.49 20.89 29.94 7.74 5.2 7.47 Hs.532634 IFI27, interferon, a-inducible protein 27
GAAGCACAAGT 7.12 47.23 29.84 24.95 6.64 4.24 3.56 Hs.433845 KRT5, keratin 5
GTGGCCACGGC 26.43 157.44 223.83 325.32 5.96 8.56 12.49 Hs.112405 S100A9, calgranulin B
GAGCAGCGCCC 36.59 215.5 277.56 362.25 5.89 7.67 10.04 Hs.112408 S100A7, psoriasin 1
GTGTGGGGGGC 8.13 42.31 31.83 29.94 5.2 3.96 3.73 Hs.514174 JUP, junction plakoglobin
GATCTCTTGGG 18.3 55.1 48.75 72.85 3.01 2.69 4.04 Hs.516484 S100A2
AAAGCACAAGT 30.5 90.53 101.5 191.6 2.97 3.36 6.37 Hs.433845 KRT6A, keratin 6A
GAAGCAGGACC 26.43 64.94 57.7 50.89 2.46 2.21 1.95 Hs.170622 CFL1, cofilin 1 (non-muscle)
CTTCCTTGCCT 22.36 53.14 55.71 48.9 2.38 2.52 2.22 Hs.2785 KRT17, keratin 17
TGTGTTGAGAG 249.05 150.55 150.22 142.7 1.65 1.64 1.72 Hs.422118 EEF1A1, eukaryotic translation elongation factor 1 a1
TCACCGGTCAG 78.27 37.39 43.77 23.95 2.09 1.77 3.22 Hs.522373 GSN, gelsolin (amyloidosis, Finnish type)
CTTCCTGTGAT 35.58 16.73 9.95 8.98 2.13 3.54 3.91 Hs.348419 SBEM, small breast epithelial mucin
GCAAGAAAGTG 25.41 7.87 5.97 4.99 3.23 4.21 5.02 Hs.523443 HBB, hemoglobin, b
ACGTTAAAGAC 191.11 52.15 38.8 35.93 3.66 4.87 5.24 Hs.350570 Sweat gland dermcidin peptide
TTACTTCCCCA 25.41 6.89 3.98 1 3.69 6.32 25.1 Hs.502745 FADS2, fatty acid desaturase 2
TAATAAAGAAT 14.23 0 0.99 2.99 28.93 14.15 4.69 Hs.2785 KRT15, keratin 15
All tags that were commonly upregulated in the three investigated inflammatory skin disorders (lichen planus, LP; atopic dermatitis, AD; psoriasis, Pso) when
compared with healthy control (HC). Given are the absolute expression as well as the relative expression (ratio) when compared with HC.
70 Journal of Investigative Dermatology (2008), Volume 128
J Wenzel et al.
Type I IFN in LP
Unclassified clustering distinguishes LP and HC from AD
and Pso
First, unclassified computer-based clustering was performed
to test our hypothesis, that gene expression profiling might be
a reliable method to distinguish LP from other inflammatory
skin disorders. Actually, unclassified clustering led to a sharp
distinction of the different skin disorders and HC. Only very
few patients clustered outside their specific disease, including
only one of the 20 patients suffering from LP, according to a
specificity of 95%. All HCs were clustered together (100%),
whereas some intersections were seen between AD and Pso.
The results are shown in Figure 2a.
Unique chemokine expression profile in LP
LP skin biopsies are characterized by a unique chemokine
expression profile, dominated by the CXCR3 ligand
CXCL9, which was specifically upregulated in all investigated
skin samples (Figure 2b) and was identified as the best
marker for LP as revealed by the SAM (Significance
analysis for Microarrays) method. Additionally, CCL21 and
CCL19 were significantly enhanced in LP, when compared
with AD, Pso, and HC. CCL13, CCL18 and, CCL22 were
strongly induced in both, LP and AD, skin samples,
whereas CCL17 and CCL27 were mainly found in AD.
CCL20 was slightly upregulated in all investigated
inflammatory skin disorders. Detailed data is given in
Table 3.
Strong IFN signature is characteristic for LP skin lesions
Several type I and type II IFN-inducible genes were
specifically upregulated in LP skin lesions, including IRF1,
IFTM1, IFTM2/3, and IFI30. Remarkably, type I IFN-specific
genes, such as MX1 and IFI27, were highly expressed in LP,
but also to a lower extent in Pso. Figure 2b depicts the
AD
AD HC
4
3
2
1
0
3
2
1
0
−1
−2
2
1
0
−1
−2
−3
−1
−2
−3
−4
LP Pso
CXCL9
Mx1
IRF1
HLA-DPB1
HLA-C
HC
LP
Pso
Figure 2. PIQOR microarray assays reveal type I IFN signature and strong expression of CXCL9 in LP. cDNA microarray-based assays (PIQOR), including
1,542 skin-associated genes, were performed to confirm the SAGE results on an individual basis. (a) The results of unclassified clustering which clearly
distinguished LP and HC from AD and Pso. (b) Examples of IFN-associated genes (chemokine ligand CXCL9, type I IFN-inducible Mx-protein,
IFN regulating factor 1, and HLA molecules DPB1 and C), which were predominantly upregulated in LP (given is the relative expression when compared
with a common reference which represents a pool of 160 samples derived from skin biopsies of patients with different skin disorders).
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expression profile of Mx1 and IRF1 in the individual patients;
detailed data is given in Table 3.
Gene expression profile reflects lesional inflammation including
MHC class I and II activation
Additionally, several MHC class I and II molecules were
specifically upregulated in LP, when compared with AD, Pso,
and HC. MHC class I molecules included HLA-A and HLA-C,
and MHC class II molecules were HLA-DPB1, HLA-DRA,
HLA-DQB1, and HLA-DPA1. Significant HLA-C expression
was found in LP, and to a lesser extent in AD. Expression
analyses furthermore showed a slight increase of apoptosis-
associated molecules (including Bax1, BCL2/3, and TRAIL)
and T-cellular inflammation in LP (data not shown). Figure 2b
exemplary shows the expression of one MHC class I
molecule (HLA-C) and one MHC class II molecule (HLA-
DPB1) in single samples; detailed data is given in Table 3.
ISH and IHC confirm strong CXCL9 expression in LP skin lesions
In subsequent studies, we sought to confirm our results with
alternative methods. ISH and IHC for CXCL9 were estab-
lished to confirm our data and to localize the expression of
CXCL9 in lesional skin. All ISH analyses were done in
duplicate in five different patients with LP. Additionally, anti-
sense labeling was performed routinely for control purposes.
These ISH investigations revealed a fair to strong expression
of CXCL9 in all investigated LP skin lesions, which was
undetectable in controls. Representative findings are given in
Figure 3a and b. IHC confirmed these findings on the protein
level. In LP, CXCL9 was seen to be strongly expressed in the
whole epidermis, just in the same areas where the CXCL9
mRNA was found. A weak CXCL9 expression was also found
in some AD and Pso skin samples, but this expression was
significantly lower than that seen in LP (Figure 3c and d).
Keratinocytes are type I IFN producers in LP skin lesions
Earlier studies and our own results provided evidence that
type I IFNs and IFN-induced chemokines might be important
for the lesional inflammation in LP. Plasmacytoid dendritic
cells are supposed to be major IFN producers in LP skin
lesions (Santoro et al., 2005; Wenzel et al., 2006). Therefore,
we were interested in the lesional expression of IFN-a and -b
in LP, and established ISH for these IFNs in our material.
Additionally, we investigated the lesional expression of MxA,
which is an established marker for type I IFN expression, by
IHC. We found a strong expression of both, IFN-a and -b
mRNA, in LP skin lesions. Importantly, IFN-a expression was
not only detectable within the inflammatory infiltrate
(probably due to plasmacytoid dendritic cells), but also in
the whole epidermis and the upper dermis. IFN-b was slightly
expressed in the dermis and predominantly seen in the basal
epidermal layers (Figure 4a). To support these findings on the
protein level, IHC labeling for the antiviral MxA protein was
performed, which is a highly specific marker for type I IFN
signaling. In LP skin lesions, MxA was strongly expressed in
epidermis and upper dermis of all investigated LP skin
lesions. In a lower extend, it was also found in Pso, whereas it
was infrequently seen in AD and absent in HC (Figure 4b).
CXCR3þ CTL dominated inflammation in LP reflects gene
expression profile
Since type I IFNs are known to drive a cytotoxic immune
response and since the CXCR3 ligand CXCL9 was the most
prominent marker for LP in the performed gene expression
analyses, we expected numerous CXCR3þ cytotoxic T cells
in the inflammatory infiltrate in LP. This prompted us to
characterize the inflammatory infiltrate in our skin samples
by IHC. As expected, all investigated skin disorders showed a
Table 3. Comparison of gene signature for
chemokines, IFNs, and MHC molecules as detected
by PIQOR analyses
Gene Ratio gene expression Mann–Whitney U-test
LP HC AD Pso LP/HC LP/AD LP/Pso
Chemokine
CXCL9 1.55 1.76 0.91 1.05 ** ** **
CCL21 0.99 0.51 0.08 0.04 * ** **
CCL19 0.88 1.28 0.18 0.69 ** ** **
CCL22 0.54 0.58 0.90 0.09 ** NS NS
CCL18 0.68 2.98 0.38 2.1 ** NS **
CCL13 0.46 0.11 0.43 0.43 ** NS **
CCL20 0.15 0.26 0.22 0.35 ** NS NS
CXCL14 0.20 0.01 0.11 0.27 NS NS **
CCL27 0.03 1.01 0.92 0.62 ** ** NS
CCL2 0.06 1.27 0.25 0.40 ** NS *
CCL17 0.51 1.54 0.64 1.31 ** ** **
IFN Signature
IRF1 0.87 1.13 0.14 0.39 ** ** **
IFITM1 0.63 0.61 0.15 0.04 ** ** **
IFI27 0.61 2.92 0.28 0.35 ** ** NS
IFI30 0.55 1.4 0.32 0.74 ** ** **
IFITM2/IFITM3 0.28 0.45 0.05 0.33 ** * **
Mx1 0.22 1.36 0.47 0.21 ** ** NS
IFIT1 0.19 0.61 0.49 0.47 ** ** **
G1P3 1.25 1.92 1.62 1.22 * NS NS
MHC
HLA_C 0.93 0.65 0.21 0.10 ** ** **
HLA_DPB1 0.83 0.96 0.03 0.65 ** ** **
HLA_DRA 0.82 0.88 0.08 0.73 ** ** **
HLA_DQB1 0.81 0.49 0.32 0.44 ** * **
HLA_DPA1 0.80 0.64 0.01 0.66 ** ** **
HLA_A 0.78 0.31 0.06 0.14 ** ** *
HLA_E 0.42 0.34 0.24 0.19 ** NS *
MHC, major histocompatibility complex.
The relative expression of the listed genes in the investigated inflammatory
skin disorders (lichen planus, LP; atopic dermatitis, AD; psoriasis, Pso) in
comparison with common reference which represents a pool of 160
samples of different skin disorders is given (ratio). Mann—Whitney –U-test
was performed to compare the expression among different diseases
(*Po0.05, **Po 0.01, NS, not significant).
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predominantly T-cellular inflammation. In AD and Pso, there
was a slight predomination of CD4þ over CD8þ cells,
whereas in LP, the number of CD8þ lymphocytes was
slightly higher. Several CD68þ macrophages accompanied
the T cells in all disorders. Importantly, in LP, nearly all of the
infiltrating lymphocytes expressed the chemokine receptor
CXCR3. Several cytotoxic cells were seen within the
inflammatory infiltrate of LP and in a lower rate also in Pso,
but were only infrequently found in AD and nearly absent in
HC. Sequential double staining for CXCR3 and GranB was
performed, which revealed the cytotoxic character of several
CXCR3þ cells in LP. Detailed data and representative
micrographs are given in Figure 5.
DISCUSSION
This study was performed to develop a skin disease-oriented
microarray and to evaluate its impact in cutaneous model
diseases. We hypothesized, that expression analyses of a
combination of pre-chosen genes might specifically identify
separate skin disorders and provide more detailed insights
into pathologic pathways, which may serve as new targets for
therapeutic intervention. LP was chosen as model disease,
since this disorder is clearly defined by clinical and
histological findings, but also shares some features with the
world’s most common skin disorders, AD and Pso, such as T-
cellular infiltration and inflammatory acanthosis.
First, SAGE analyses, which give an overview of the
complete gene activity, were performed using mRNA pools of
selected skin disorders. These results, completed by literature
data, were the basis to design a skin disease-oriented
microarray. This microarray was used to characterize
individual mRNA samples, extracted from whole skin
biopsies of patients with definite inflammatory skin disorders
(LP, AD, Pso, and HC; n¼ 20, respectively). Importantly,
unclassified clustering based on a preselected group of 80
genes associated with the GO keywords, ‘‘interferon,’’
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Figure 3. ISH and IHC confirm significant CXCL9 expression in LP skin lesions. ISH and IHC for CXCL9 were established to confirm lesional CXCL9
expression in LP on the mRNA and the protein level. (a) Typical findings of CXCL9 ISH in LP compared with sense control (Bar¼0.1 mm), (b) an overview
of overall investigated samples (n¼ 5). (c and d) These results were confirmed by IHC, typical findings of CXCL9 expression in LP, AD, Pso, and HC concludes
data of all investigated biopsies (nX5, respectively). Statistical data is given in mean7SEM (*¼Po0.05, **¼ Po0.01, Mann–Whitney U-test. Bar¼ 0.1 mm).
www.jidonline.org 73
J Wenzel et al.
Type I IFN in LP
‘‘apoptosis,’’ ‘‘MHC,’’ ‘‘chemokine,’’ ‘‘B cell,’’ and ‘‘T cell’’,
revealed a sharp distinction of these groups. All HC samples
clustered together, and only one of the 20 LP samples was
grouped outside the LP cluster, according to a specificity of
95%. Some overlaps were seen between AD and Pso, where
four patients, respectively, were grouped in the reciprocal
cluster, probably reflecting the more common genetic and
pathogenetic background of these disorders (Bovenschen
et al., 2005; Hoffjan and Epplen, 2005).
The LP gene expression profile was dominated by IFN-
inducible genes (Mx1, IFITM1, and G1P3) and IFN-associated
inflammation (NF-kB, CXCL9, MHC class I, and apoptosis).
These findings were concordantly seen in SAGE and PIQOR
analyses and in accordance with earlier reports, providing
evidence for a pathogenic role of type I IFN-driven
inflammation in LP (Fah et al., 1995; Flier et al., 2001; Pinto
et al., 2003; Santoro et al., 2005; Wenzel et al., 2006). Our
ISH and IHC analyses confirmed a strong type I IFN signature
in LP skin lesions, which clearly distinguished LP from AD
skin lesions. Some of the IFN inducible genes, as well as a fair
expression of the type I IFN-inducible protein MxA was also
seen in Pso, but clearly weaker than in LP. This supports
earlier concept for a role of type I IFN in Pso, which,
however, appeared to be less relevant than in LP (Eriksen
et al., 2005). Common upregulated genes in AD, Pso, and LP-
included cytokeratins (CK5 and CK17) and some S100
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Figure 4. Type I IFNs (IFN-a/IFN-b) are largely produced in LP lesions. Lesional type I IFN signaling was investigated by ISH for IFN-a1 and IFN-b.
(a) Representative findings for these ISHs in comparison with sense control (Bar¼ 0.1 mm). (b) Results of all these experiments are concluded (n¼ 5).
(c and d) The MA protein, which is an established and highly specific marker for type I IFN production, was stained by IHC. Typical findings in the
investigated skin disorders give an overview about all investigated samples (nX5, respectively). Statistical data is given in mean7SEM (*Po0.05, **Po0.01,
Mann–Whitney U-test).
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proteins (A2, A7/psoriasin, and A9/calgranulin), and reflected
common clinical features like lymphocytic infiltration and
inflammatory acanthosis (Ichikawa et al., 1997; Willis et al.,
1998; Eckert et al., 2004; Martinsson et al., 2005).
Chemokines and their receptors play a crucial part in the
recruitment of leukocytes into inflammatory sites. LP skin
lesions were specifically characterized by the expression of
CXCL9, CCL19, and CCL21, chemokines which are closely
associated with type I IFN-driven inflammation (Parlato et al.,
2001; Sharif et al., 2004; Badr et al., 2005). Among the tags
identified by SAGE analysis, CXCL9 was the most specific
marker for LP. In accordance with these findings, CXCL9 was
also the most specific marker for LP in PIQOR microarray.
These results were confirmed by ISH and IHC, which
revealed a strong CXCL9 signaling in the epidermis and the
upper dermis in exactly those areas with strong type I IFN
expression and lymphocytic invasion. Our findings conclude
with the earlier work of Tensen et al. (1999), who found an
expression of CXCL9 in basal epidermal layer in 5/5 LP skin
lesions but only 1/7 Pso lesions, with the studies of Spandau
et al. (1998), which revealed strong expression of MIG/
CXCL9 and IP10/CXCL10 in LP skin samples, and with the
work of Ichimura et al. (2006), who found a strong expression
of CXCL9 by reverse transcriptase-PCR in LP.
Since CXCL9 is a selective attractant for activated T cells,
bearing the chemokine receptor CXCR3 (Tensen et al., 1999;
Flier et al., 2001) and since type I IFNs are known to enhance
the cytotoxic capacity of lymphocytes (Guillot et al., 2005),
we thought cytotoxic CXCR3þ CD8þ cells to be present in
LP skin lesions. This hypothesis was supported by some
earlier studies, providing evidence for a pathogenic role of
CD8þ cells in LP. Bovenschen et al. (2005) found activated
CD8þ T cells to be a hallmark of LP skin lesions, when
compared with AD and Pso, and Sugerman et al. (2000)
established CD8þ ‘‘autocytotoxic’’ T-cell lines out of LP skin
biopies, recognizing autologous keratinocytic antigens. San-
toro et al. (2004) found a close association between
epidermal invasion of CTLs and epidermal apoptosis in situ,
and our own recent findings revealed expression of CXCR3
on 60–90% of lesional lymphocytes in LP (Wenzel et al.,
2006). Here, we demonstrated by IHC that, as indicated by
gene expression profiling, CXCR3þ cytotoxic T cells are a
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Figure 5. Characterization of the inflammatory infiltrate by IHC reveals CD8-dominated T-cellular inflammation in LP, including numerous CXCR3þ
cytotoxic cells. IHC using monoclonal antibodies specific for CD3, CD4, CD8, CD20, CD68, CXCR3, granzyme B, and Tia1 was performed to characterize the
lesional infiltrate in the investigated inflammatory skin disorders. (a) Typical findings of CD8 and CXCR3 expression (Bar¼ 0.1 mm) and (b) concludes this data
(nX10, respectively). Given is the mean number of cells per high-power field (Original magnification200)7SEM. (c) Sequential double staining was
performed to confirm coexpression of CXCR3 (brown) and granzyme B (red) in infiltrating cells.
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significant subset of infiltrating T lymphocytes in LP.
CXCR3þ CTL were seen in the junctional zone, infiltrating
the basal epidermal layers and appeared to be the major
effector cells. Additionally, a significant expression of MHC
class I and II was seen in PIQOR analyses, which is in
accordance with earlier immunohistochemical analyses
concerning the expression of these molecules in LP (Farthing
et al., 1992; Sugerman et al., 2000).
This study demonstrated that gene expression profiling
followed by unclassified clustering is a reliable method to
identify patients with LP in the chosen context and reflects
known pathogenetic factors. Therefore, gene expression
profiling appears to be an interesting method in dermato-
logical diagnostics as well as in experimental investigation.
However, gene expression profiling so far can only solve one
part of the puzzle. Data generated with pooled samples
(SAGE) should be confirmed in several single patients, as
done by microarray analysis and also on the protein level.
Importantly, only ISH and IHC can give clear information
about the localization of the expressed markers, which is
central to develop new pathogenic models and to proceed
from gene expression profiling to functional molecular
analyses. In the chosen context, comparing LP with other
clearly defined inflammatory skin disorders, gene expression
profiling followed by unclassified clustering was able to
identify 95% of LP samples correctly. This results show that a
‘‘diagnostic’’ use of gene expression profiling is principally
possible. However, its use is clearly limited by the quality of
gene expression data available for all skin disorders, by the
cost of this technique, and by the more complicated handling
of skin biopsies to obtain mRNA of sufficient quality. In our
opinion, gene expression profiling is not superior to
established clinical and histological diagnostic procedures,
but may yield important additional information which might
help to improve our understanding of pathogenic mechan-
isms and uncover new therapeutic targets.
Here, CXCL9 was identified to be the most significantly
induced chemokine in LP and strong expression of several
IFN-inducible genes point to a functional relevance of type I
IFNs in this disease. On the basis of these findings, we
provided first evidence that keratinocytes are, in addition to
plasmacytoid dendritic cells (Santoro et al., 2005; Wenzel
et al., 2006), type I IFN producers in LP skin lesions on their
own. These observations support the experimental develop-
ment of new strategies for therapeutic intervention. For
example, anti-CXCL9 antibodies have successfully been used
in acute allograft rejection, and might also be an interesting
tool in LP (Belperio et al., 2003). Additionally, inhibition of
type I IFN production, which is being considered in other
IFN-dependent disorders, such as lupus erythematosus
(Crow, 2003; Lee and Reeves, 2006), might be considered.
MATERIALS AND METHODS
Skin samples
In this approach, lesional skin biopsies of 20 patients with LP, HC,
AD, and Pso were analyzed, respectively. These samples were
collected in a collaborative project of Miltenyi Biotec with the
Dermatology Departments of the Universities of Aachen, Cologne,
and Bonn. Only biopsies taken from untreated patients with typical
skin lesions were included. Diagnosis was confirmed by standard
histological techniques in every case. All patient- and biopsy-
specific data were stored in the SkinSAYSTM database (see
Supplementary Text) that was programmed as part of the study for
data management and correlation. The study was approved by the
Local Ethnic Committees and has fulfilled the Declaration of
Helsinki Principles. All patients signed a consent form. Skin samples
were divided into two parts immediately after excision. One part was
flash-frozen in liquid nitrogen and later processed for mRNA
isolation. A second part was fixed in 5% formalin solution over
night, and was proceeded for conventional histological investiga-
tion, ISH, and IHC.
RNA isolation
Isolation of total RNA from skin excision biopsies was performed
using TriReagent (Sigma, St Louis, MO) and the NucleoSpin 96 RNA
Kit (Macherey & Nagel, Dueren, Germany). RNA was quantified by
photometrical measurement, and the integrity was checked using a
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
SAGE analysis
SAGE analysis of total RNA was performed according to the
‘‘MicroSAGE Detailed Protocol’’, available at http://www.sagenet.
org, with minor alterations. For each SAGE library, mRNA obtained
from 20 to 22 biopsies of normal and diseased skin, respectively,
was pooled to generate disease-specific skin transcriptomes. For data
analysis, the Miltenyi SAGE analysis package was used as described
previously (Pennartz et al., 2004).
PIQOR analysis
A topic-defined PIQOR (Parallel Identification and Quantification of
RNAs) microarray (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) comprising 1,542 genes was designed on the basis of
SAGE analysis. This microarray was used to reveal a gene expression
profile for every individual patient. Hybridization, scanning, and
data analysis were performed according to the PIQOR protocol as
described in detail elsewhere (Bosio et al., 2002; Pennartz et al.,
2004), and comply to the MIAME (Minimum information about a
microarray experiment) standards. Briefly, Cy5-labeled single patient
samples were hybridized versus a Cy3-labeled common reference.
The reference represented a pool of 160 RNAs derived from skin
biopsies of patients with several skin disorders. General microarray
data analysis, including hierarchical clustering and statistical
analysis of microarrays (SAM), was performed using the TIGR TMEV
software (Saeed et al., 2003).
Functional classification
Functional classification of the genes was performed according
to the classification of the Gene Ontology Consortium (http://
www.geneontology.org, accessed 1 July 2006).
ISH
Slides were deparaffinized in xylene and rehydrated through a series
of graded dilutions of ethanol (100, 95, 75, and 50%). Then sections
were treated with proteinase K and post-fixed in 4% paraformalde-
hyde. EasyProbeTM Transcription Templates (Miltenyi Biotec GmbH)
for IFN-a, -b, and CXCL9 were used as template for generation of
76 Journal of Investigative Dermatology (2008), Volume 128
J Wenzel et al.
Type I IFN in LP
digoxigenin-labeled hybridization probes. Digoxigenin labeling was
performed according to the protocol of the supplier (Roche,
Grenzach-Wyhlen, Germany). Visualization was performed using
alkaline phosphatase-conjugated anti-dig fab fragments using Fast
Red or levamisole as chromogen (DAKOTM, Hamburg, Germany).
The expression was scored semiquantitatively (0 to þ þ þ ) and the
mean was calculated.
Histology and immunohistology
Sections were prepared from formalin-fixed, paraffin-embedded skin
biopsies. Standard hematoxylin and eosin and periodic acid Schiff
staining was performed for diagnostic purposes. The inflammatory
infiltrate was characterized by IHC using monoclonal antibodies
specific for CD4 (1F6, NovocastraTM, Newcastle, UK), CD3 (F7238),
CD8 (C8/144B), CD20 (L26), and CD68 (PGM1; all from DAKOTM,
Hamburg, Germany) following the manufactures protocol. Addi-
tionally, we analyzed the expression of type I IFN-associated marker
proteins and chemokines. MxA (M143, dilution 1:100; Professor
Haller, University of Freiburg), CXCL9/Mig (MAB392; R&DTM,
Minneapolis, MN), and CXCR3 (1C6, dilution 1:100; PharMingenTM,
San Diego) labeling was performed after heat antigen retrieval as
described before (Wenzel et al., 2005). The cytotoxic capacity of
infiltrating lymphocytes was determined using monoclonal anti-
bodies specific for Tia1 (Clone 26gA10F5; ImmunotechTM, Marseille,
France) and Granzyme B (GrB7; DAKOTM). Appropriate isotype-
matched controls were included. Visualization was performed using
the LSAB2TM staining kit (DAKOTM) with Fast Red as chromogen for
sequential double staining in combination with the Envision
SystemTM (DAKOTM) with 3,30-diaminobenzidine as chromogen.
Results were evaluated on masked specimens by two experienced
dermatopathologists (JW and TT) independently. Cells were counted
per three high-power fields ( 200) and the mean number was
calculated. The expression of CXCL9 and MxA was scored semi-
quantitatively (0¼ no expression; þ ¼weak expression; þþ ¼ fair
expression; þþþ ¼ strong expression).
Statistical analysis
Statistical analyses were performed computer based by SPSSTM
software (version 12). The nonparametrical Mann–WhitneyU-test
was used to compare the expression of the different genes detected
by microarray analyses and the extent of inflammatory infiltrate in
different disorders and HC, revealed by IHC. Po0.05 was
considered to be significant (*) and Po0.01 as highly significant (**).
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